Medthority· @Medthority · X·· 3 天前评分70
正文 · 原文
#ESMO26
More from Krascendo-1:
📊 Confirmed ORR: 58% with divarasib vs 32% with sotorasib/adagrasib
📉 Grade 3–4 TRAEs: 24.6% vs 34.5%
📉 TRAE discontinuations: 4.8% vs 11.7%
No emergent new safety signals
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedX #MedSky @FSkoulidis
30 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Medthority · x.com